Acorn AI is designed to answer questions across all phases of drug development, making data “liquid” to help pharma make quick “go/no-go” decisions, accelerate clinical trials, and demonstrate value.
Taconic Biosciences’ new solution enables researchers to generate and maintain mice with custom microbiome profiles, alterations to which can significantly affect drug efficacy.
Charles River Laboratories has extended its ongoing collaboration with the CHDI Foundation by five-years – and is closing its San Diego, CA-based research model production facility.
Circuit Clinical partners with the University at Buffalo’s genomics and biorepository program to add personalized medicine capabilities to its service offering lineup.
Bringing together the food industry’s know-how and pharma’s manufacturing expertise, the new joint venture from Lonza and Chr. Hansen is positioned to pioneer the live biotherapeutic products space – addressing medical needs not met with ‘conventional’...
Catalent Pharma invests $5m in drug development center of excellence to expand its hot melt extrusion capabilities for formulation and drug delivery method optimization.
Twist Bioscience, a synthetic DNA provider, enters a strategic collaboration with LakePharma to bolster antibody discovery and optimization for biologic drug development.
Metrion Biosciences looks to partner and move its lead candidate into clinical trials later this year fueled by a funding round which will also see its drug discovery services expand throughout 2019.
Horizon Discovery is working with St George’s University Hospital and EMQN to develop reference material for non-invasive prenatal testing, which is being increasingly adopted in the UK and abroad.
Sinclair Research and Turner Scientific sign an exclusive partnership through which the CROs will offer ototoxicity testing services – and improve regulatory guidance regarding the ears to protect patients, says company executive.
Cell One Partners formally launches its consulting services and aims to be a long-term partner to its clients, supporting the development of cell and gene therapies – a market which raised more than $13.3bn in 2018.
The industry in March saw new c-suite appointments at CRF Bracket, PCI Pharma Services, George Clinical, and Paragon Bioservices – as well as moves to boost medical device and DMPK services at Premier Research and Sygnature Discovery, respectively.
Lundbeck extends its research collaboration with the drug discovery services provider Enamine to help “intensify its search for quality lead compounds.”
LabCorp’s collaboration with Mission Bio will use single cell-sequencing technology to understand the genetics of rare cell populations, which could be key to making clinical trials successful, says CEO.
Clinical trials in the UK are reportedly declining as the country grapples with Brexit – a change which could make access to preclinical and bioanalytical research materials, including NHPs, problematic, says QPS.
Evotec AG is partnering with the Mark Foundation for Cancer Research to discover and develop first-in-class therapeutics in oncology using its new drug discovery platform.
WuXi LabNetwork enters an agreement with Science Exchange enabling users to order compounds directly following an increased demand for specialty chemicals.
Using its proprietary bioprocessing technology, Cellesce is scaling the production of breast organoids for drug discovery research – with plans to expand into other areas of unmet medical need, says CEO.
WuXi STA becomes the preferred CDMO partner for Beta Pharma as the company launches a Phase II clinical trial in China and begins preclinical research for an additional target.
Optibrium develops software for drug discovery and today announces a collaboration with InfoChem GmbH, a cheminformatics company, to provide users with a computer-aided synthesis design tool.
Evotec is partnering with a global non-profit research group to develop a pipeline of novel antibiotics after integrating Sanofi’s infectious disease unit last year.
In response to a growing interest in alternative testing methods, SenzaGen signs a license agreement with MB Research Labs to expand the use of its animal-free testing platform.
The clinical informatics company Ovation.io secures $5m in Series A funding to expand its platform designed to help diagnostic labs become a “keystone of precision medicine in their community,” says CEO.
Drug development advisory firm Rosa & Co. enters research agreement with Chugai pharmaceutical to provide access to PhysioPD research services for translational biology.
Regeneron and UK Biobank announce human sequencing data resource for global research and to accelerate improved patient care through outcome algorithms.
Datathon participants identify five repurposable drug candidates, applying AI to identify genes of interest and support target identification – a task that previously would have taken years, says industry expert.
Parexel boosts its oncology team, Premier Research has a new COO joining from PPD, and SGS names a new biologics manager, among other new hires in February.
Lonza enters private label partnership to manufacture and globally commercialize AllCell’s hematopoietic primary cells to provide greater access to researchers.
Charles River is set to acquire Citoxlab for €448m ($510m) in cash, a deal which would bolster the CRO’s safety assessment portfolio to support its long-term organic growth aspirations, says CEO.
Ligand Pharmaceuticals enters an agreement with Genagon to provide access to its drug development platform capable of producing fully human antibodies.
Backed by a private equity investment, Taconic Biosciences is focusing on its growth strategy, with plans to add capacity, pursue acquisitions, and develop new products, says the company’s new CEO.
People on the move in January include new CEOs at Lonza, Taconic, MaSTherCell, Pii, and Wasdell, among several other c-suite shakeups and new hires as the industry kicks off the New Year.
QPS is expanding ‘aggressively’ at its US-based headquarters, rebuilding on a rolling basis to support a growing demand for gene therapy treatments, says VP.
Aetion aims to advance the adoption of and standards for real-world evidence backed by a strategic investment from several global biopharma and health care companies.
Charles River is offering Toxys’ ToxTracker in an agreement that will see its portfolio of genetic toxicology assays expand to customers in North America.
Real world evidence extraction is one area where Sanofi is using NLP text mining, a technology with applications across the R&D pipeline, from target identification to clinical trial design and pharmacovigilance.
